34
Views
1
CrossRef citations to date
0
Altmetric
CLINICAL SCIENCE

Ocular Manifestations in Korean Patients with Multiple Sclerosis

, , &
Pages 55-61 | Accepted 05 Nov 2007, Published online: 08 Jul 2009
 

Abstract

Objective: The overall influence of race on ocular manifestations in multiple sclerosis (MS) is unknown. Methods: This study reviewed ocular manifestations in Korean MS patients from 1996 to 2004. Results: Of the 121 patients, 62 (51%) showed ocular manifestations that comprised optic neuritis (ON) in 52 (42.9%), ocular motor deficits in 11 (9.1%), and visual field defects in 2 (1.7%). Of the 27 patients (45 eyes) with ON whose medical records were available for results of the ophthalmologic tests, 19 patients (70%) experienced painless visual loss and 8 eyes (17.8%) showed severe disc edema. Twenty-nine of 37 patients (78.4%) with isolated ON as an initial manifestation showed normal brain MRI and twenty-seven (73%) negative oligoclonal band (OCB). Of the ocular motor findings, unilateral internuclear ophthalmoplegia (6 patients) was the most common. Conclusions: Korean MS patients showed lower frequencies of ON and ocular motor deficits than Caucasian and Japanese patients. The known risk factors associated with increased risk of developing MS in several western studies did not apply to Korean ON. Our study suggests that ocular manifestations of MS may differ among the races.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.